Receptor News and Research

RSS

Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate

Palatin Technologies, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate.

1 Dec 2009

Control over male fertility and hope for low sperm count

A new research report published in the December 2009 print issue of The FASEB Journal could one day give men similar type of control over their fertility that women have had since the 1960s. That's because scientists have found how and where androgenic hormones work in the testis to control normal sperm production and male fertility. This opens a promising avenue for the development of "the pill" for men. The discovery also offers hope to those who cannot have children because of low sperm counts.

1 Dec 2009

New research suggests high fat, energy-dense foods may activate genes that make us obese

Those extra helpings of gravy and dessert at the holiday table are even less of a help to your waistline than previously thought. According to a new research report recently appearing online in The FASEB Journal (http://www.fasebj.org), a diet that is high in fat and in sugar actually switches on genes that ultimately cause our bodies to store too much fat.

1 Dec 2009

Study provides new insight into the mechanism of bacterial invasion protein

Spoiled meat is one of the sources for Listeria infections leading to listeriosis. Pregnant women, newborns and immune compromised people are susceptible for a severe progression of this disease. Firstly, the pathogen breaches the intestinal barrier and thus enters the body. The key for further spreading is the invasion protein internalin B that is located on the bacterial surface.

30 Nov 2009

B cells and their antibodies defend against microbes and control commensal microflora

Microbes populated the earth long before any eukariotic cell. Therefore, in order to survive, mono and multi-cellular organisms had to develop mechanisms of adaptation, cohabitation and defense against bacteria, fungi and viruses. One of these mechanisms is mediated by immunoglobulins in the serum and at mucosal surfaces.

27 Nov 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

The Swedish biotech company Karo Bio today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

26 Nov 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

Findings show the relationship between neurotransmitter dopamine and ADHD

Scientists at the California Institute of Technology (Caltech) have uncovered evidence of a primitive emotion-like behavior in the fruit fly, Drosophila melanogaster.

26 Nov 2009

Erbitux drug can reverse rare stomach disorder, report researchers

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week.

25 Nov 2009

Study reveals that ghrelin can increase resistance to Parkinson's disease

Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of Neuroscience.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

24 Nov 2009

Oxagen completes £16 Million Series C round funding

Oxagen Limited, a drug discovery and development company specializing in inflammation, announced today the successful completion of a £16 Million ($26.7 Million) Series C round led by Novartis Venture Funds.

24 Nov 2009

Scientists identify factors behind chronic coughing

Scientists have revealed how environmental irritants such as air pollution and cigarette smoke cause people to cough, in research published today in the American Journal of Respiratory and Critical Care Medicine. The

24 Nov 2009

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.

24 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

Inadequate asthma control is present in 26% to 45% of children, says review

Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

23 Nov 2009

Receptos raises $25 million through Series A financing

Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.

23 Nov 2009

Receptor News and Research

Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate

Control over male fertility and hope for low sperm count

New research suggests high fat, energy-dense foods may activate genes that make us obese

Study provides new insight into the mechanism of bacterial invasion protein

B cells and their antibodies defend against microbes and control commensal microflora

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Findings show the relationship between neurotransmitter dopamine and ADHD

Erbitux drug can reverse rare stomach disorder, report researchers

Study reveals that ghrelin can increase resistance to Parkinson's disease

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

Oxagen completes £16 Million Series C round funding

Scientists identify factors behind chronic coughing

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

New initiative launched to take care of patients with sickle cell disease

Inadequate asthma control is present in 26% to 45% of children, says review

Receptos raises $25 million through Series A financing

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News